Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Globe Newswire•27/07/2026•08:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.